Literature DB >> 9507563

Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction.

K Kaneko1, T Kanda, T Yokoyama, Y Nakazato, T Iwasaki, I Kobayashi, R Nagai.   

Abstract

While an overproduction of interleukin-6 (IL-6) has been observed in patients with acute myocardial infarction (AMI), its clinical significance and localization in the ischemic myocardium have not been elucidated. We examined immunohistochemically the expression of IL-6 in 12 autopsied patients with AMI who had died within seven days of the infarction. Twenty sections of ischemic myocardium and nine of the coronary arteries involved were stained with anti-IL-6 and anti-atrial natriuretic peptide (ANP). The diameter of the myocardium was analyzed. The greatest expression of IL-6 in the infarcted myocardium occurred in patients who had died three to four days after the onset (2.7 +/- 0.4), as judged by a scheme for grading IL-6 expression. Patients who died within one to two days (1.0 +/- 0.3) or five to eight days (0.6 +/- 0.4) less frequently showed an overproduction of IL-6. The IL-6-positive myocardium co-expressed ANP and was significantly (p < 0.05) hypertrophied, when compared with the IL-6-negative myocardium. The diameter of IL-6-positive myocardial myocytes was significantly (p < 0.02) increased in patients who died within one to two days (1.6 +/- 0.2), three to four days (1.8 +/- 0.3), or five to eight days (2.0 +/- 0.2) after the AMI. The involved coronary arteries expressed IL-6 in the intimal and smooth muscle cells, as did atherosclerotic coronary arteries not involved in AMI. An overproduction of IL-6 was confirmed in the injured myocardium with hypertrophy in patients who died of AMI within seven days after onset. The hypertrophied injured myocardium co-expressed IL-6 and ANP. The expression of IL-6 in the myocardium in AMI appears to be associated with the mechanism of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9507563

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  17 in total

1.  Transforming growth factor-beta(1) expression in dilated cardiomyopathy.

Authors:  J E Sanderson; K B Lai; I O Shum; S Wei; L T Chow
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

2.  Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study.

Authors:  G Hetet; B Grandchamp; C Bouchier; V Nicaud; L Tiret; G Roizès; M Desnos; K Schwartz; R Dorent; M Komajda
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Contrast enhanced magnetic resonance angiography and pulmonary venous anomalies.

Authors:  F Godart; S Willoteaux; C Rey; B Cocheteux; C Francart; J P Beregi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

4.  Effects of cardiac resynchronisation on maximal and submaximal exercise performance in advanced heart failure patients with conduction abnormality.

Authors:  D Birnie; L P Soucie; S Smith; A S Tang
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

5.  Reciprocal increase of circulating interleukin-10 and interleukin-6 in patients with acute myocardial infarction.

Authors:  N Kotajima; T Kimura; T Kanda; A Kuwabara; Y Fukumura; M Murakami; I Kobayashi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

6.  Percutaneous aortic valve replacement: will we get there?

Authors:  Y Boudjemline; P Bonhoeffer
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

7.  Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin.

Authors:  S Verma; A S Dumont; A Maitland
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 8.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

9.  Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).

Authors:  Aramesh Saremi; Robert J Anderson; Ping Luo; Thomas E Moritz; Dawn C Schwenke; Mathew Allison; Peter D Reaven
Journal:  Atherosclerosis       Date:  2008-08-05       Impact factor: 5.162

10.  Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Tracey G Simon; Maria Esther Perez Trejo; Robyn McClelland; Ryan Bradley; Michael J Blaha; Irfan Zeb; Kathleen E Corey; Matthew J Budoff; Raymond T Chung
Journal:  Int J Cardiol       Date:  2018-05-15       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.